NASDAQ$ICUI
ICU Medical Inc. · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter results, with revenue generally in line with expectations and updated fiscal year 2024 guidance.
ICU Medical announced third quarter 2024 results with revenue of $589.1 million, compared to $553.3 million in the same period last year. GAAP net loss was $(33.0) million, or $(1.35) per diluted share. Adjusted diluted earnings per share was $1.59, compared to $1.57 for the third quarter of 2023. The company updated its fiscal year 2024 guidance for GAAP net loss and adjusted EBITDA.
- Third quarter revenue was $589.1 million, an increase from $553.3 million in the same period last year.
- GAAP gross profit for the third quarter was $204.9 million, compared to $183.9 million in the prior year.
- GAAP net loss for the third quarter was $(33.0) million, or $(1.35) per diluted share.
- Adjusted diluted earnings per share for the third quarter was $1.59, compared to $1.57 for the third quarter of 2023.
Headline financials
Revenue & EPS history
ICU Medical · Revenue · Quarterly
$589M
Revenue by segment
ICU Medical · $391M total across 2 segments · Q3 2023
- Consumables$242M+71.5%61.9%
- Infusion Systems$149M+69.7%38.1%
Forward guidance
For fiscal year 2024, the company updated its estimates of GAAP net loss to a range of $(130) to $(122) million and GAAP diluted loss per share to a range of $(5.28) to $(4.98). The company updated the estimated range of its full year 2024 guidance of adjusted EBITDA from a range of $345 million to $365 million to a range of $355 million to $365 million and updated the estimated range of diluted earnings per share from a range of $4.95 to $5.35 to a range of $5.40 to $5.70.
Tailwinds
- Adjusted EBITDA is expected to be between $355 million and $365 million.
- Adjusted diluted earnings per share is expected to be between $5.40 and $5.70.
- Interest, net is projected at $97 million.
- Stock compensation expense is expected to be $46 million.
- Depreciation and amortization expense is projected at $223 million.
Headwinds
- GAAP net loss is estimated to be between $(130) million and $(122) million.
- GAAP basic/diluted loss per share is estimated to be between $(5.28) and $(4.98).
- Restructuring, strategic transaction and integration expenses are projected at $65 million.
- Quality and regulatory initiatives and remediation costs are expected to be $30 million.
- Change in fair value of contingent earn-out is estimated at $(4) million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+0.3%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.3%
Avg return
30 days after
52%
38 / 73 earnings
Positive
+22.4%
Q2 2024
Best reaction
-33.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | -0.8% | +10.7% | |
| Q4 2025 | +4.8% | +3.6% | -16.3% | |
| Q3 2025 | +8.2% | +7.3% | +9.9% | |
| Q1 2025 | -3.3% | -4.9% | -6.9% | |
| Q4 2024 | -2.3% | -4.1% | -6.4% | |
| Q3 2024 | -1.9% | -5.8% | -7.1% | |
| Q2 2024 | +22.4% | +19.7% | +31.2% | |
| Q1 2024 | -0.1% | +6.3% | +7.6% | |
| Q4 2023 | +6.5% | -0.2% | +1.6% | |
| Q3 2023 | -17.8% | -20.2% | -15.9% | |
| Q2 2023 | -15.2% | -15.6% | -16.8% | |
| Q1 2023 | +13.3% | +8.7% | +3.9% | |
| Q4 2022 | -3.6% | -4.2% | -7.3% | |
| Q3 2022 | +6.7% | +21.4% | +11.8% | |
| Q2 2022 | -7.4% | -4.7% | -8.0% | |
| Q1 2022 | -10.4% | -15.0% | -14.9% | |
| Q4 2021 | +5.8% | +9.0% | +4.3% | |
| Q3 2021 | +2.1% | +2.7% | -6.4% | |
| Q2 2021 | +0.7% | +1.2% | +6.1% | |
| Q1 2021 | -5.0% | -6.5% | -2.1% | |
| Q4 2020 | -5.5% | -6.8% | -4.4% | |
| Q3 2020 | +0.6% | +4.8% | +5.6% | |
| Q2 2020 | +8.8% | +5.0% | +9.8% | |
| Q1 2020 | -8.8% | -13.7% | -8.0% | |
| Q4 2019 | -4.2% | -4.8% | -8.2% | |
| Q3 2019 | +6.9% | +4.3% | +6.8% | |
| Q2 2019 | -33.3% | -31.2% | -36.6% | |
| Q1 2019 | -2.7% | -3.3% | -2.2% | |
| Q4 2018 | +2.5% | -4.9% | -2.8% | |
| Q3 2018 | -10.6% | -14.8% | -10.6% | |
| Q2 2018 | +2.2% | +2.4% | +3.7% | |
| Q1 2018 | +1.4% | +4.3% | +12.4% | |
| Q4 2017 | +4.6% | +7.5% | +9.1% | |
| Q3 2017 | +8.6% | +10.1% | +11.7% | |
| Q2 2017 | -2.9% | -2.4% | +3.4% | |
| Q1 2017 | -0.2% | -0.1% | +6.2% | |
| Q4 2016 | +0.7% | -1.0% | +1.5% | |
| Q3 2016 | -0.4% | -0.9% | +2.5% | |
| Q2 2016 | +7.5% | +6.1% | +8.6% | |
| Q1 2016 | -1.0% | — | — | |
| Q4 2015 | -8.7% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | +19.9% | — | — | |
| Q1 2015 | +7.3% | — | — | |
| Q4 2014 | +2.2% | — | — | |
| Q3 2014 | +13.6% | — | — | |
| Q2 2014 | +10.5% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | +0.1% | — | — | |
| Q3 2013 | +3.0% | — | — | |
| Q2 2013 | -6.7% | — | — | |
| Q1 2013 | +1.3% | — | — | |
| Q4 2012 | +1.1% | — | — | |
| Q3 2012 | +3.7% | — | — | |
| Q2 2012 | -0.2% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q4 2011 | +1.9% | — | — | |
| Q3 2011 | +0.2% | — | — | |
| Q2 2011 | -3.9% | — | — | |
| Q1 2011 | +2.2% | — | — | |
| Q4 2010 | +0.1% | — | — | |
| Q3 2010 | -0.9% | — | — | |
| Q2 2010 | +3.4% | — | — | |
| Q1 2010 | -1.0% | — | — | |
| Q4 2007 | -1.0% | — | — | |
| Q4 2009 | -1.0% | — | — | |
| Q3 2009 | -0.8% | — | — | |
| Q3 2008 | -0.8% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q2 2008 | -3.9% | — | — | |
| Q1 2009 | -3.9% | — | — | |
| Q4 2008 | -3.9% | — | — | |
| Q1 2008 | -3.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro